PerkinElmer

Halal Rating :
Comfortable
Last Price $118
Market Cap $15.35b
1D Change

-2.92 %

1 Year Change

8.7 %

Next Earnings Date

Yet to be announced

Company Overview

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revenue Sources

Pass

Based on the company's SEC filings and revenue breakdowns, PerkinElmer's primary revenue streams come from diagnostic tools, analytical instruments, and laboratory services. These are halal business activities as they provide real value through scientific and medical advancement. No evidence was found of revenue from prohibited sources such as alcohol, gambling, or other haram activities.

Reliance on Interest

Reporting Date Total Revenue Total Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 29, 2024 $684.05m $583.69m - $-2,200,000.0 0.00% 0.38%
June 30, 2024 $691.68m $605.02m - $-940,000.0 0.00% 0.16%
March 31, 2024 $649.92m $615.37m - $9.57m 0.00% 1.55%
Dec. 31, 2023 $1.37b $1.34b - $45.78m 0.00% 3.43%

Analyzing the last four quarters of financial data, interest expenses relative to total expenses have remained consistently below the 5% threshold. The highest interest expense ratio observed was approximately 3.4% of total expenses in Q4 2023, with subsequent quarters showing lower ratios. Interest income is negligible across all periods.

Operational Ethics

Pass

Review of company disclosures and operations shows no significant ongoing relationships with entities involved in human rights violations. While the company has global operations, no evidence was found of material collaboration with the Chinese Communist Party or current operations in Israel.

Rating Justification

Member Vote

Agree: 0 Disagree: 0

Login to vote on this

Comments

0 Comments

Login to join the discussion

Recent News & Updates